Cardiff Oncology
CRDF
117 hedge funds and large institutions have $122M invested in Cardiff Oncology in 2024 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 40 increasing their positions, 16 reducing their positions, and 3 closing their positions.
1,133% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 3
258% more capital invested
Capital invested by funds: $34.1M → $122M (+$87.8M)
253% more call options, than puts
Call options by funds: $4.64M | Put options by funds: $1.32M
150% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 16
41% more funds holding
Funds holding: 83 → 117 (+34)
14.82% more ownership
Funds ownership: 27.41% → 42.23% (+15%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
+$16.8M |
| 2 |
O
OrbiMed
New York
|
+$4.81M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$4.04M |
| 4 |
LCM
Laurion Capital Management
New York
|
+$1.8M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.59M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
-$989K |
| 2 |
BC
BIT Capital
Berlin,
Germany
|
-$676K |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$635K |
| 4 |
Renaissance Technologies
New York
|
-$373K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$251K |
CRDF Hedge Fund Activity: Q4 2024 in Review
117 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Cardiff Oncology (CRDF) for Q4 2024, worth a combined $122M — up 258% from $34.1M a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new CRDF positions and 3 closed out — a net gain of 34 holders — while 40 added to existing stakes and 16 trimmed.
The largest buyer was Commodore Capital, opening a new position worth an estimated $16.8M. The largest seller was Two Sigma Advisers, cutting an estimated $989K.
- 117 institutional investors held Cardiff Oncology (CRDF) as of Q4 2024, up from 83 in Q3 2024.
- Funds reported $122M of Cardiff Oncology stock for Q4 2024, up 258% quarter-over-quarter.
- 37 funds opened new Cardiff Oncology positions in Q4 2024 and 3 closed out, a net change of +34 holders.
- The largest Cardiff Oncology buyer in Q4 2024 was Commodore Capital, an estimated $16.8M added.
- The largest Cardiff Oncology seller in Q4 2024 was Two Sigma Advisers, an estimated $989K sold.
Based on aggregated 13F filings for Q4 2024.